

QIAGEN launches novel tuberculosis test for high-burden regions

20 October 2021 | News

QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited



QIAGEN N.V. has announced the launch and CE marking of QIArearch® QuantIFERON®-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing access to easy and reliable TB testing, especially in high burden countries, low-resource regions.

QIArearch® QuantIFERON®-TB is a portable device that enables the ultrasensitive digital detection of TB infection with an end-to-end workflow that is simple and cost efficient, and increases access to reliable Interferon Gamma Release Assay (IGRA) testing.

A quantum leap from the traditional TB skin test, QuantIFERON-TB uses blood samples to test for interferon-gamma molecules released from T-cells that have come into contact with TB bacteria. QIArearch QuantIFERON TB testing requires one patient visit and produces an easy-to-read result in 20 minutes after sample incubation, with the ability to record and send results for improved data management, making it ideal for TB screening programs.

QIAGEN will work with commercial distribution partners as well as the Stop TB Partnership's Global Drug Facility to ensure affordable access across all high burden, low and middle-income countries. In parallel, QIAGEN will continue its close collaboration with a variety of international organizations and public health institutions to help drive scale-up through innovative implementation projects.